17th week of 2011 patent applcation highlights part 44 |
Patent application number | Title | Published |
20110098307 | CRYSTALLINE OF ESZOPICLONE, ITS COMPOSITION, PREPARATION AND USES THEREOF - The present invention discloses a crystalline form of S-zopiclone having a powder X-Ray diffraction spectrum excited by Cu-Ka radiation with characteristic peaks expressed in terms of 28 at about 11.08°, about 12.38°, about 15.86°, about 17.88°, about 19.98° and about 20.58°; a DSC thermogram with a peak at about 207.7° C. and an infrared absorption spectrum (IR) with characteristic peaks at about 3078 cm | 2011-04-28 |
20110098308 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE - Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists. | 2011-04-28 |
20110098309 | METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS - Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers from amyloid β1-42 monomers using acylhydrazide compounds. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers using acylhydrazide compounds. | 2011-04-28 |
20110098310 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF - The present invention relates to compounds of the general formula (I) wherein R | 2011-04-28 |
20110098311 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES - The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions. | 2011-04-28 |
20110098312 | METHODS FOR PREVENTING THE DEVELOPMENT OF RETINOPATHY BY THE ORAL ADMINISTRATION OF NNR LIGANDS - Method and compositions for delaying the onset or progression of retinopathy, including administering at least one neuronal nicotinic ligand are disclosed. | 2011-04-28 |
20110098313 | POSITIVE ALLOSTERIC MODULATORS (PAM) - The present invention relates to phenylethynyl compounds of formula I | 2011-04-28 |
20110098314 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA - The use of HMG-CoA reductase inhibitors (e.g., statins) to treat glaucoma, control intraocular pressure, preserve the trabecular meshwork, protect against ocular neurodegeneration and/or protect against glaucomatous retinopathy is described. The preferred HMG-CoA reductase inhibitors, which are statins having an RI value of 0.2 to 0.7 (e.g., pravastatin), are administered via topical application to the affected eye(s) of the patient. | 2011-04-28 |
20110098315 | PHARMACEUTICAL COMPOSITIONS OF ROSUVASTATIN CALCIUM - This invention is related to pharmaceutical compositions of rosuvastatin or pharmaceutically acceptable salts thereof especially calcium salt with sodium carbonate anhydrous which has effects on dissoltion profiles in 0.1 N HCI medium provided that using of sodium carbonate anhydrous should be presence in the range of from about 0.5% to about 2% by weight. | 2011-04-28 |
20110098316 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS - The present invention provides chromane derivatives as transient receptor potential vanilloid (TRPV) modulators. In particular, the compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. | 2011-04-28 |
20110098317 | USE OF UNSATURATED SPHINGOSINE COMPOUNDS AS CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER - The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. This invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases. | 2011-04-28 |
20110098318 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING BREAST CANCER - The present invention relates to the use of farnesyl protein transferase inhibitors for preparing pharmaceutical compositions for treating advanced breast cancer. | 2011-04-28 |
20110098319 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY - The invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, useful for all the known clinical applications of the latter, which show physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterize butyrate. The new compounds are amide derivatives which can be synthesized by reaction of the corresponding fatty acid halide with a naturally occurring amino acid, phenylalanine or a suitable derivative thereof, and which are in a poorly hygroscopic, easily weighable form, stable to acids and alkalis and able to release the acid at the small and large bowel level in a constant manner over time. They do not have disagreeable odors and are practically tasteless, thus allowing the manufacture of preparations for oral administration also suitable for the therapy of chronic diseases and in the pediatric field. | 2011-04-28 |
20110098320 | Lactam Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 - This invention relates to novel compounds of the Formula (I), (I*), (Ia), (Ib), (Ic), (Id), (Ie), (If), (If*), (Ig), (Ih), (Ij), (Ik), (ll1-3), (Im1-3), (In1-3), (lo1-2), (Ip1-9), (Iq1-9), (Ir1-9) and (Is1-3) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell. | 2011-04-28 |
20110098321 | SALTS OF METHYL 2-((R)-(3-CHLOROPHENYL)((R)-1-((S)-2-(METHYLAMINO)-3-((R)-TETRAHYDRO-2H-P- YRAN-3-YL)PROPYLCARBAMOYL)PIPERIDIN-3-YL)METHOXY)ETHYLCARBAMATE - Mucic acid salts of a compound represented by the following structural formula: | 2011-04-28 |
20110098322 | PREPARATION OF NOVEL 1,3-SUBSTITUTED UREAS AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE - The present invention provides compounds that can inhibit the activity of soluble epoxide hydrolases. In particular, the present invention provides compounds of Formula I. | 2011-04-28 |
20110098323 | INHIBITORS OF BACTERIAL BIOFILM FORMATION - Organic compounds are described for use in inhibiting or preventing formation of bacterial biofilms. | 2011-04-28 |
20110098324 | PROLYL HYDROXYLASE INHIBITORS - The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I) | 2011-04-28 |
20110098325 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyridine benzamide and pyrazine benzamide compounds (referred to herein as PDBA and PZBA compounds) which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc. | 2011-04-28 |
20110098326 | 2-FLUOROTHIAZOLE DERIVATIVES USEFUL AS IMAGING AGENTS; METHODS OF SYNTHESIS, AND METHODS OF USE | 2011-04-28 |
20110098327 | Hepatitis C Virus Inhibitors - This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. | 2011-04-28 |
20110098328 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS - The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 2011-04-28 |
20110098329 | CATALYZED CARBONYLATION IN THE SYNTHESIS OF ANGIOTENSIN II ANTAGONISTS - One embodiment disclosed in the invention is the efficient synthesis of halogenated biaryl starting material via Grignard chemistry and the use thereof. Another embodiment of the invention is the reaction of catalyzed carbonylation of the 3′-(2′-halo-biphenyl-4-ylmethyl)-1,7′-dimethyl-2′-propyl-1H,3′H-[2,5′]bibenzoimidazolyl (TLMH) using either gaseous carbon monoxide in a solvent mixture containing water; or formic acid salts optionally together with acetic acid in anhydrous solvent. | 2011-04-28 |
20110098330 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS - A compound having selective modulating activity at the alpha 2B and or alpha 2C adrenergic receptor subtypes is represented by the general Formula (1): wherein R | 2011-04-28 |
20110098331 | HALOALKYLSUBSTITUTED ARYLOXYALKYLIMIDAZOLINES FOR USE AS PESTICIDES - The present invention relates to novel imidazoline derivatives and their use as insecticidal, acaricidal, mollus and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests. A compound of formula (I): and the salts and N-oxides thereof. | 2011-04-28 |
20110098332 | Insecticides for Increasing the Crop Yield - The present invention relates to the use of at least one insecticide selected from GABA antagonists for increasing the crop yield of at least one plant variety and to a method for increasing the crop yield of at least one plant variety by treating the propagules from which it is to grow with at least one GABA antagonist insecticide. | 2011-04-28 |
20110098333 | METHODS FOR TREATING OR PREVENTING BRAIN INFECTIONS - The invention is directed to methods of treating organ specific infections in a host organism by administering compounds that target host receptors and/or host cellular signaling molecules to prevent a pathogen from infecting the organ. For example, the administration of a compound to prevent a pathogen from crossing the blood-brain barrier to prevent a brain infection. | 2011-04-28 |
20110098334 | NOVEL CRYSTALLINE FORM OF CALCIUM ZOFENOPRIL - The present invention relates to a novel anhydrous crystalline form of zofenopril calcium of formula (I), chemically known as (4S)-1-[(2S)-3-(benzoylthio)-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt or hemi-calcium salt. The present invention further relates to a process for the preparation of the new crystalline form of zofenopril calcium, its use in pharmaceutical compositions and the use of the new crystalline form and compositions in the treatment of hypertension and various other diseases. | 2011-04-28 |
20110098335 | NOVEL COMPOUNDS - The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof, | 2011-04-28 |
20110098336 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR - A compound represented by the formula (I) according to claim | 2011-04-28 |
20110098337 | Inhibitors of RTP801 and their use in disease treatment - The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein. | 2011-04-28 |
20110098338 | RNA Interference for the Treatment of Heart Failure - The present invention relates to targeted RNAi for the treatment of heart failure by modulating defective cardiac Ca | 2011-04-28 |
20110098339 | C2ORF18 AS TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS - Described herein are objective methods for detecting or diagnosing a predisposition to developing cancer, particularly pancreatic cancer. In one embodiment, the diagnostic method involves the step of determining an expression level of C2orf18 using anti-C2orf18 antibody. The present invention further provides methods of screening for therapeutic agents useful in the treatment of a C2orf18-associated disease, such as a cancer, e.g. pancreatic cancer, methods of inhibiting the cell growth and treating or alleviating their symptom. The invention also features products, such as polynucleotides, polypeptides, and vectors double-stranded molecules, antibodies, vectors and compositions composed thereof. | 2011-04-28 |
20110098340 | ANTISENSE MODULATION OF BCL2-ASSOCIATED X PROTEIN EXPRESSION - Antisense compounds, compositions and methods are provided for modulating the expression of BCL2-associated X protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding BCL2-associated X protein. Methods of using these compounds for modulation of BCL2-associated X protein expression and for treatment of diseases associated with expression of BCL2-associated X protein are provided. | 2011-04-28 |
20110098341 | USE OF ID4 FOR DIAGNOSIS AND TREATMENT OF CANCER - The invention relates to a method of determining whether a human subject is suffering from or at risk for developing pancreatic cancer by determining the methylation level of an ID4 gene promoter or the expression level of an ID4 gene in a biological sample from a human subject. Also disclosed are a method of analyzing the methylation level of an ID4 gene promoter or the expression level of an ID4 gene in a pancreatic cancer cell, and a method of inhibiting the methylation of an ID4 gene promoter or enhancing the expression of an ID4 gene by contacting a pancreatic cancer cell with a compound that decreases the methylation level of an ID4 gene promoter or increases the expression level of an ID4 gene in the cell. | 2011-04-28 |
20110098342 | METHODS OF DETECTING LONG RANGE CHROMOSOMAL INTERACTIONS - The present invention relates to a method of monitoring epigenetic changes comprising monitoring changes in conditional long range chromosomal interactions at at least one chromosomal locus where the spectrum of long range interaction is associated with a specific physiological condition, the method comprising the steps of: —(i) in vitro crosslinking of said long range chromosomal interactions present at the at least one chromosomal locus; (ii) isolating the cross linked DNA from said chromosomal locus; (iii) subjecting said cross linked DNA to restriction digestion with an enzyme that cuts at least once within the at least one chromosomal locus; (iv) ligating said cross linked cleaved DNA ends to form DNA loops; (v) identifying the presence of said DNA loops; wherein the presence of DNA loops indicates the presence of a specific long range chromosomal interaction. | 2011-04-28 |
20110098343 | Antisense Formulation - A room temperature stable and minimal aggregate liquid formulation comprises an oligonucleotide comprising Seq ID No. 1: or comprising a variant oligonucleotide in which no more than 3 non-sequential bases are different from Seq. ID NO. 1 and an aqueous carrier comprising a aggregation-preventing compound selected from the group consisting of mono and disaccharides and/or sugar alcohols. | 2011-04-28 |
20110098344 | DRUG CARRIER - A drug carrier characterized by mainly containing a polyethylene-glycol-modified phospholipid and a cationic lipid and containing the polyethylene-glycol-modified phospholipid in a concentration within a specific range. The drug carrier, which is of the in-blood residence type, is characterized by comprising a polyethylene-glycol-modified phospholipid represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: | 2011-04-28 |
20110098345 | Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics - The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI. | 2011-04-28 |
20110098346 | NUCLEIC ACID MOLECULE AND METHOD OF TARGETING GENE EXPRESSION TO GLIOMAS - There is presently provided a nucleic acid molecule comprising a glial-specific promoter; a coding sequence for a transgene; and a plurality of miRNA target sites. Each miRNA target site binds an miRNA that is down-regulated in .a glioma cell compared to a normal glial cell, and the glial-specific promoter and the plurality of miRNA target sites are both operably linked to the coding sequence for the transgene. | 2011-04-28 |
20110098347 | PHOSPHOROUS BINDER FOR TREATMENT OF KIDNEY DISEASE - The present invention relates to oral compositions which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The dietary supplements and pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy. | 2011-04-28 |
20110098348 | CANNABIS SATIVA PLANTS RICH IN CANNABICHROMENE AND ITS ACID, EXTRACTS THEREOF AND METHODS OF OBTAINING EXTRACTS THEREFROM - The present invention relates to plants producing, as their major cannabinoid cannabichromenic acid (CBCA) or its neutral (decarboxylated) form cannabichromene (CBC), hereafter jointly referred to as CBC(A). It additionally relates to: • A botanical material obtainable from said plants; • A botanical raw material (BRM), • An extract including a botanical drug substance (BDS) and a purified BDS; • A formulation comprising the BRM, BDS, purified BDS or other extract; • The use of the BRM, BDS, purified BDS or other extract in the manufacture of a medicament; • A method of deriving plants yielding a high proportion of the cannabinoid CBC (A) at the expense of other cannabinoids; • A method of cultivating plants such that they yield a high proportion of the cannabinoid CBC(A) at the expense of other cannabinoids; and • A method of extracting CBC(A) from said plants. | 2011-04-28 |
20110098349 | CATHECHINS FOR THE TREATMENT OF SYSTEMIC AA AMYLOIDOSIS - A method of treating an amyloid disease characterized by AA amyloid fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed catechins. The therapeutic amount of the catechin is selected for efficacy in treating AA amyloid fibrillogenesis in a mammalian subject. | 2011-04-28 |
20110098350 | SUBSTITUTED CYCLOHEXYLIDENE-ETHYLIDENE-OCTAHYDRO-INDENE COMPOUNDS - Novel substituted cyclohexylidene-ethylidene-octahydro-indene compounds and compositions comprising the same are described. The compounds exhibit profound anti-proliferative effects, in comparison to other compounds known for their anti-cancer and anti-hyperproliferative ability. Methods of use of such compounds and compositions are described for treating a variety of cancers, inflammatory and other hyperproliferative diseases and disorders. | 2011-04-28 |
20110098351 | Lactone compounds which can be used as antioxidant agents in pharmaceutical, cosmetic or food compositions and their method of preparation - The subject of the present invention is specific lactone compounds which can be used as antioxidant agents in pharmaceutical or cosmetic compositions or in food products, the said compounds containing a naphthalene ring onto which two lactone units are grafte. | 2011-04-28 |
20110098352 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS - Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases. | 2011-04-28 |
20110098353 | Compounds for Imaging and Therapy - A metal complex of formula (III) wherein: M is a transition metal and A1, A2, X, X′, Y, L1′, R1′ and R2′ are as defined herein, is useful in medical imaging and therapy. | 2011-04-28 |
20110098354 | METHOD OF PREPARING A LATANOPROST OPHTHALMIC SOLUTION AND THE RESULTING SOLUTION - A method of solubilizing an analog active agent of the prostaglandin F2α, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and, a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment. | 2011-04-28 |
20110098355 | METHOD OF PREPARING A LATANOPROST OPHTHALMIC SOLUTION AND RESULTING SOLUTION - A method of solubilizing an analog active agent of the prostaglandin F2α, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment. | 2011-04-28 |
20110098356 | Production and Purification of Esters of Polyunsaturated Fatty Acids - The present invention includes methods for producing and purifying esters of polyunsaturated fatty acids that include reacting a composition having triglycerides with polyunsaturated fatty acid residues in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides. The composition can be a polyunsaturated fatty acid-containing composition that has not been conventionally processed. The reacted composition can be further processed by distillation. | 2011-04-28 |
20110098357 | VAGINAL SUPPOSITORY COMPRISING LACTIC ACID - The present invention relates to a vaginal suppository comprising an inert vehicle and lactic acid or a salt thereof for the treatment and/or prophylaxis of disorders in the urogenital tract. It also relates to the use of such a suppository for the production of a medicament for the treatment and/or prophylaxis of disorders in the urogenital tract as well as to a method for the treatment and/or prophylaxis of disorders in the urogenital tract. | 2011-04-28 |
20110098358 | HUMAN BETA3 ADRENERGIC RECEPTOR LIGAND, AND FOOD OR PHARMACEUTICAL PRODUCT CONTAINING THE SAME - A human adrenergic β | 2011-04-28 |
20110098359 | Compositions and Methods for Treatment of Glaucoma - A new use for paracetamol in a method of treating glaucoma, which method comprises administering to a patient in need of such treatment 500 mg to 1000 mg of paracetamol in oral format 4 to 6 hourly. An ophthalmic solution is also provided containing between 0.1 to 5% of paracetamol which is administered as one to two drops in each eye 4 to 6 hourly. The ophthalmic solution further includes one or more of the following excipients: hydroxypropylmethylcellulose, benzalconium chloride, polyacrylic acid such as Teargel®. | 2011-04-28 |
20110098360 | ADAMANTANE DERIVATIVE FOR INHIBITING TOXICITY OF AMYLOID OLIGOMER - Disclosed is a pharmaceutical composition containing a compound useful for inhibiting neurotoxicity caused by beta amyloid. The pharmaceutical composition of the present disclosure contains 1,3,5,7-tetrakis(aminomethyl)adamantane, an analogous compound thereof or a salt thereof as an active ingredient. The inventors have studied methods for reducing the toxicity of beta amyloid oligomers based on the formation mechanism of dodecamers in consideration of the fact that especially the dodecamers from among the beta amyloid oligomers exhibit a significant activity as a toxin for synapses and neurons in cranial nerve diseases. The inventors have confirmed that the disclosed compound can induce structural epitope deformation of the dodecamer and thereby reduce toxicity of the beta amyloid oligomers. The pharmaceutical composition containing the compound is useful for preventing and treating cranial nerve diseases developed by the toxicity of beta amyloid oligomers, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, macular degeneration, prion disease, and the like (see FIG. | 2011-04-28 |
20110098361 | Composition to enhance the bioavailability of curcumin - A composition for enhanced bioavailability of curcumin including purified curcuminoid and purified essential oil of turmeric. A method to prepare a composition for enhanced bioavailability of curcumin having purified curcuminoid and purified essential oil of turmeric. | 2011-04-28 |
20110098362 | Application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation/chemotherapy sensitization - Use of 2-bromo-isovanillin in the preparation of an anticancer medicament and/or radio- and chemotherapy sensitizing medicament is disclosed. The medicament for the treatment of cancers and/or for radio- and chemotherapy sensitization comprising 2-bromo-isovanillin as active ingredient provided herein has the following features: (1) low toxicity, without evident adverse effects; (2) significant therapeutic effect, with remarkable proliferation inhibiting and pro-apoptotic effects in tumor cells; (3) a broad-spectrum anticancer activity; (4) suitable to be used in combination with antimetabolites, to enhance the effects and meanwhile lower the toxicity, and also to reduce multi-drug resistance; (5) convenient and safe administration, the main route being oral. | 2011-04-28 |
20110098363 | AMPHIPHILIC MOLECULES WITH A TRIAZINE CORE - The present invention is directed to chemical compounds of formula (I) wherein A1 is selected from the group consisting of alkyl, aryl, alkylaryl and (formula A), A2, A3, A4, A5 and in case A1 is (formula A) also A6 and A7 comprise a polymer selected from the group consisting of [EO] | 2011-04-28 |
20110098364 | NOVEL INVERSE LATICES BASED ON FATTY ALCOHOL ETHERS, AND COSMETIC, DERMOCOSMETIC, DERMOPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITIONS COMPRISING - Novel inverse latices based on fatty alcohol ethers of formula R | 2011-04-28 |
20110098365 | SALT PRODUCT - A method of preparing a salt product comprises the steps of: (i) providing a mixture which comprises salt dissolved in a solvent, said mixture further containing an organic material that is solid under ambient temperature conditions; and (ii) atomising said mixture and evaporating said solvent to produce a salt product comprised of particles of salt incorporating said organic material. The organic material may be a polymer such as a carbohydrate (e.g. maltodextrin or Gum Arabic). Novel salt products are disclosed which comprise hollow particles having a shell formed for individual crystallites of salt. The salt product is useful as a seasoning for food and may be used in lower amounts than conventional salt to provide the same taste. Particular advantages are obtained in the baking of bread. | 2011-04-28 |
20110098366 | Pharmaceutical Preparation in Containers that are Pervious to Water Vapor and Have Improved Stability - The present invention relates to a pharmaceutical preparation, comprising a mixture of at least one pharmaceutical active ingredient, at least one alcohol component and at least one triglyceride component, in a plastic container, characterized in that the plastic has a water vapour permeability of no more than 3.0 g/m | 2011-04-28 |
20110098367 | METHOD & APPARATUS FOR PROCESSING FISCHER-TROPSCH OFF-GAS - This invention concerns methods and apparatus for processing Fischer-Tropsch off-gas comprising the following steps: a) subjecting Fischer-Tropsch off-gas to at least a water gas shift reaction and partial CO | 2011-04-28 |
20110098368 | CONTROLLING SYNTHESIS OF METAL SULFIDE CATALYSTS - Methods and apparatus relate to catalysts and preparation of the catalysts, which are defined by sulfides of a transition metal, such as one of molybdenum, tungsten, and vanadium. Precipitation forms the catalysts and occurs in a slurry media in which the pH is adjusted. Exemplary uses of the catalysts include packing for a methanation reactor that converts carbon monoxide and hydrogen into methane. | 2011-04-28 |
20110098369 | NANOCOMPOSITE ION EXCHANGE HYDROGELS - A method for preparing a nanocomposite ion exchange hydrogel and a nanocomposite ion exchange hydrogel are disclosed. A monomer is graft polymerized onto a carbohydrate to form a carbohydrate graft copolymer. Before, during, or after graft polymerizing, an adsorbent is modified with a cationic surfactant to form a surfactant modified adsorbent. Next, the surfactant modified adsorbent is dispersed and entrapped in the carbohydrate graft copolymer and crosslinked to form a crosslinked carbohydrate graft copolymer. The crosslinked carbohydrate graft copolymer is then isolated. In some embodiments, the pH of the crosslinked carbohydrate graft copolymer can be adjusted. | 2011-04-28 |
20110098370 | SULFONATED POLY 2-(PHENYL ETHYL) SILOXANE POLYMER ELECTROLYTE MEMBRANES - The present invention provides polymer electrolyte membranes (PEM) based upon sulfonated poly 2-(phenyl ethyl)siloxane (SPPES) prepared in a one-pot procedure. This includes the SPPES homopolymer as well as random copolymer of SPPES with various non-sulfonated polysiloxanes. Copolymerization with poly 2-(phenyl ethyl)siloxane greatly improves the mechanical stability of the film compared to a SPPES homopolymer. Proton conductivity of the copolymer, though it is less than that of the homopolymer and Nafion, is comparable to other PEMs in the literature. Both SPPES based membranes show good water retention at temperature greater than 100° C., which indicates they may be suitable for use in high temperature PEM fuel cells. | 2011-04-28 |
20110098371 | Proton-Conducting Polymeric Poly(Arylene Ether)s with Pendant Phenyl Sulfonic Acids - Disclosed are sulfonated polymers of formula (I) or a salt thereof: wherein X is (a) or (b), R is hydrogen or an organic moiety, n is an integer from 10 to 10,000, p is 1 or 2, and m is 0 or 1 for a particular monomer unit such that the polymer has a degree of sulfonation of 0.50 or greater. Such polymers are useful in proton exchange membranes (PEMs) having high ion exchange capacity with higher proton conductivity than Nafion™, while having lower methanol permeability and lower water uptake than previously disclosed polymers. | 2011-04-28 |
20110098372 | FOAMABLE POLYAMIDES - Thermoplastic molding compositions comprising | 2011-04-28 |
20110098373 | OPEN CELL FOAM AND MANUFACTURE OF OPEN CELL FOAM PRODUCTS - A foam form sheet material having a first large surface comprising substantially only closed cells and an opposite large surface and an interior comprising substantially only open cells. This material comprises a cross linked olefin thermoplastic polymer or copolymer. The foam is made by mixing the polymer with a blowing agent and a cross linking agent. The mixture is maintained in a two roll mill means for a time sufficient to initiate cross linking and to initiate foaming to form closed cells. The sheet material is then disposed in a second two roll mill means having a nip that is larger than the thickness of the foamed sheet material and maintained under elevated temperature and pressure sufficient to initiate further cross linking and foaming. The fully cross linked cell foam is then compressed to rupture the closed cells that are disposed in the interior to form open cells. | 2011-04-28 |
20110098374 | BONE CEMENT MIXTURE FOR PRODUCING AN MRT-SIGNALING BONE CEMENT - The invention relates to a bone cement mixture for producing an MRT-signaling bone cement and to an MRT-signaling bone cement produced from said mixture. The bone cement mixture of the invention includes:
| 2011-04-28 |
20110098375 | DENTAL ADHESIVE COMPOSITION - [Problems] A dental adhesive composition containing an acid group-containing polymerizable monomer, that can be used as a dental adhesive material or a primer. The dental adhesive composition has excellent durability of adhesion exhibiting further improved adhering strength and durability of adhesion enabling teeth to be more strongly adhered to a composite resin or a prosthetic over extended periods of time. | 2011-04-28 |
20110098376 | Aqueous Coating Compositions with De Minimis Volatile Emissions - The present invention relates to an aqueous coating composition comprising a treated latex polymer dispersion with less than about 50 ppm of unreacted monomers. The latex polymer dispersion can be treated by various means, including stripping and chasing, to remove unreacted monomers from the dispersion. Unreacted monomers significantly contribute to paint odor. In an innovative aspect of the present invention, the synergistic combination of the treated latex dispersion with pigments and other low or zero-VOC additives results in an aqueous coating composition with de minimis levels of volatile emissions, low odor, and paint performance comparable to premium latex paints. | 2011-04-28 |
20110098377 | Method of Controlling Water Production Through Treating Proppants With RPMS - Water production from a subterranean formation is inhibited or controlled by pumping a fluid containing coated particles through a wellbore into the formation. The particles have been previously coated with a relative permeability modifier (RPM). Upon contact with water, the RPM coating expands or swells and inhibits and controls the production of water. The RPM may be a water hydrolyzable polymer having a weight average molecular weight greater than 100,000. The particles may be conventional proppants or gravel. | 2011-04-28 |
20110098378 | RUBBER COMPOSITIONS INCLUDING METAL-FUNCTIONALIZED POLYISOBUTYLENE DERIVATIVES AND METHODS FOR PREPARING SUCH COMPOSITIONS - A composition includes a vulcanizable diene rubber, a silica filler, and a metal-functionalized polyisobutylene succinic anhydride derivative. In one embodiment the composition has a reduced amount of oil and may include no oil. A tire tread composition includes, a silica filler, a metal-functionalized polyisobutylene succinic anhydride derivative, a rubber matrix, an optional oil, and one or more components selected from the group consisting of carbon black, vulcanizing agent, vulcanization accelerator, tackifier resin, antioxidant, wax, peptizer, vulcanization retarder, activator, processing additive, plasticizer, pigments, and antiozonant. A method for making the rubber composition and the tire tread is also provided. | 2011-04-28 |
20110098379 | Halogen-Free Flame Retarding Masterbatch with Low Phosphorous Content, Composition and Process for Preparing the Same and Flame Retarding Article Containing the Same - Disclosed herein is a composition for preparing a halogen-free flame retarding masterbatch with low phosphorous content. The flame retarding masterbatch includes a phosphorus-containing flame retardant in an amount of about 0.1-6 wt %, a sulfur-containing flame retardant in an amount of about 0.1-5 wt %, a tertiary or quaternary ammonium salt having tri- or tetra-functional groups in an amount of about 0.1-5 wt %, a thermoplastic polymer in an amount of about 79-99.6 wt %, and a dispersing agent in an amount of about 0.1-5 wt % in the composition. | 2011-04-28 |
20110098380 | POLYPHENOLIC COMPOUNDS AND EPOXY RESINS COMPRISING CYCLOALIPHATIC MOIETIES AND PROCESS FOR THE PRODUCTION THEREOF - Epoxy resins and mixtures of polyphenolic compounds which comprise cycloaliphatic moieties, processes for the production thereof and mixtures and cured products which comprise these resins and/or mixtures. | 2011-04-28 |
20110098381 | Adhesive formulation and also method for the treatment of reinforcing inserts - The present invention relates to an adhesive formulation in the form of an aqueous dispersion with a solids content of 10 to 40% by weight relative to the adhesive formulation, for the treatment of reinforcing inserts for the production of reinforced polymer products, 100% by weight of the solids containing
| 2011-04-28 |
20110098382 | STRUCTURAL ADHESIVES - An adhesive formulation comprising i) an adduct of an epoxy resin and an elastomer, ii) a phenoxy resin; a core/shell polymer; iv) a curing agent which provides a structural adhesive with improved low temperature impact strength particularly useful for bonding metal especially in the automotive industry. | 2011-04-28 |
20110098383 | Composite comprising nanosize powder and use of the composite - A composite is formed from at least one base material and at least one filler powder mixture dispersed in the base material. The filler powder mixture has a filler powder fraction and at least one further filler powder fraction. The filler powder fraction has an average powder particle diameter (D50) selected from the range from 1 μm to 100 μm and the total proportion of the filler powder mixture in the composite (degree of fill) is above 50% by weight. The further filler powder fraction has a further average powder particle diameter selected from the range from 1 nm to 50 nm and the proportion of the further filler powder fraction in the filler powder mixture is selected from the range from 0.1% by weight to 50% by weight. A high degree of fill can be achieved at a low viscosity in the presence of nanosize filler particles. The composite is particularly suitable as embedding composition (pourable resin system). | 2011-04-28 |
20110098384 | Production of amino lignin and amino lignin cellulose resins and adhesives - Flame retardant and water resistant products are produced from bio-based materials such as lignin cellulose containing materials. The lignin cellulose materials are modified by the method of delignification. The method of this invention utilizes an amino compound in an aqueous solution to react with the lignin in the lignin cellulose and the amino lignin and freed lignin becomes water soluble. The amino compound also reacts with the non-water soluble lignin still attached to the cellulose and also to the cellulose that is produced. Other products are produced in this method such as carbohydrates, hemi-cellulose, rosins, waxes, alcohols and other products. The amino lignin, lignin, amino lignin and amino cellulose is reacted with many organic and inorganic compounds such as aldehydes, polyisocyanates, epoxies, polycarboxylic acids, vegetable oils and many other compounds to produce resins and adhesives which may be used to produce products such as molded products, particleboard, plywood, ABS, etc. which are flame retardant and water resistant. | 2011-04-28 |
20110098385 | PROCESS FOR CROSS-LINKING BITUMEN/POLYMER COMPOSITIONS HAVING REDUCED EMISSIONS OF HYDROGEN SULPHIDE - The invention relates to a method of preparing crosslinked bitumen/polymer compositions having reduced emissions of hydrogen sulphide, in which, while operating at temperatures between 100° C. and 230° C. and with stirring, for a duration of at least ten minutes, at least one bitumen or mixture of bitumens is brought into contact with at least one polymer and at least one crosslinking agent, said crosslinking agent being represented by the general formula HS—R—SH where R represents a saturated or unsaturated, linear or branched, cyclic and/or aromatic hydrocarbon-based group having 2 to 40 carbon atoms, optionally comprising one or more heteroatoms, and that does not comprise a C═O carbonyl function and/or a O—C═O carboxylate function. | 2011-04-28 |
20110098386 | PRODUCTS HAVING IMPROVED FLAME RESISTANCE - The present invention relates to flame-retardant compositions containing:
| 2011-04-28 |
20110098387 | DISPERSANT FOR HYDRAULIC COMPOSITION - The present invention provides a dispersant for a hydraulic composition, containing (A) a polymer composed of structural units, not less than 70% by weight of which are derived from a monomer represented by the following formula (1) and (B) a naphthalenesulfonic acid-formaldehyde condensate at a weight ratio of components (A) to (B), (A)/(B), of 1/99 to 75/25: | 2011-04-28 |
20110098388 | POLYBUTYLENE TEREPHTHALATE RESIN COMPOSITION AND MOLDED ARTICLE THEREOF - The present invention provides a polybutylene terephthalate resin composition, having performance of high durability and the like in a cold cycle environment, and having high strength. Specifically, relative to 100 parts by weight of a polybutylene terephthalate resin (A) having 30 meq/kg or less of the amount of terminal carboxyl groups, there are added a carbodiimide compound (B) in an amount of 0. 3 to 1.5 equivalents of the carbodiimide functional group when the amount of carboxyl terminal group in the polybutylene terephthalate resin (A) is set as 1, 20 to 100 parts by weight of a fibrous filler (C), and 5 to 15 parts by weight of an elastomer (D). | 2011-04-28 |
20110098389 | Functional reinforcing filler and method of Preparing the same - Provided are a functional reinforcing filler and a method of preparing the same, and more particularly, a functional reinforcing filler including inorganic particles having a surface modified by an organic silanepolyol obtained by hydrolyzing an organic alkoxysilane compound and a method of preparing the sane. The functional reinforcing filler has hydrophobicity and reactivity. If the functional reinforcing filler is used to prepare rubber, a coupling agent is not required, and the rubber does not emit volatile organic compounds (VOCs). In particular, a tire prepared using the functional reinforcing filler may have low rolling resistance and excellent wet traction. | 2011-04-28 |
20110098390 | Process for Making Mixed Triglyceride Plasticizer From Benzoic and Toluic Acid - Provided are compositions, processes for making, and processes for using mixed triglycerides as plasticizers. Triglyceride plasticizers can be produced by recovery of linear or branched C | 2011-04-28 |
20110098391 | Non-Dripping Flame Retarding Masterbatch , Composition and Process for Preparing the Same and Flame Retarding Article Containing the Same - Disclosed herein is a composition for preparing a non-dripping flame retarding masterbatch. The flame retarding masterbatch includes a fire retardant in an amount of about 0.1-15.0 wt %, a crosslinking agent in an amount of about 0.1-1.5 wt %, a thermoplastic polymer in an amount of about 76.5-99.5 wt %, a crosslinking initiator in an amount of about 0.01-2.0 wt %, and a dispersing agent in an amount of about 0.1-5.0 wt % in the composition. | 2011-04-28 |
20110098392 | COMPOUNDS HAVING A GUANIDINE STRUCTURE AND USE OF SAME AS ORGANOPOLYSILOXANE POLYCONDENSATION CATALYSTS - The present invention relates to an organopolysiloxane composition that can be vulcanized at room temperature into an elastomer that is crosslinked by polycondensation and that does not contain alkyltin-based catalysts which exhibit toxicity problems. | 2011-04-28 |
20110098393 | INSULATOR HAVING EXCELLENT ARC RESISTANCE - A highly heat-resistant fluororesin, such as tetrafluoroethylene resin or tetrafluoroethylene-perfluoroalkyl vinyl ether copolymer, is filled with 0.5 to 1 weight % of a non-black insulating pigment that has a heat resistance such that discoloration does not occur when the fluororesin is baked. Green insulating pigment whose main component is a TiO | 2011-04-28 |
20110098394 | COATING COMPOSITION COMPRISING AN ALKOXYSILANE, A POLYSILOXANE, AND A PLURALITY OF PARTICLES - The present invention is directed to a coating composition, such as a substantially clear coating composition, which comprises (1) an alkoxysilane, (2) a polysiloxane, (3) a plurality of particles, and (4) curing agent that is reactive with the polysiloxane. The coating composition of the present invention can exhibit increased physical properties, such as scratch resistance, when compared to similar coating compositions that lack the components disclosed herein. | 2011-04-28 |
20110098395 | Organic Vegetable Oil Based Resin and Preparation Method Thereof - Disclosed are organic, UV resistant epoxy resins derived largely from vegetable oil based materials. More specifically, the present invention provides a virtually non-toxic, hypoallergenic UV resistant resin and method of producing and using the same that gives off substantially no VOCs and no disagreeable odors. The composition comprises a vegetable oil-based polyfunctional carboxylic acid, a cycloaliphatic anhydride, and an epoxy compound either of bicyclic difunctional epoxy resin, epoxidized vegetable oil or epoxidized polymer chains. The composition further comprises a catalyst and a wetting agent. In its cured state the material is leather like and exhibits high tensile strength as well as unusually high, totally reversible elongation. In an alternative embodiment, the resin comprises a cyclic anhydride (Lindride 16E). With increased amounts of cyclic anhydride, increased heat distortion temperature is exhibited; all while maintaining a high reversible elongation and high tensile strength In an additional alternative, an increased amount of Chromium III Octoate is used and in another alternative Phosphoric Acid. | 2011-04-28 |
20110098396 | RESIN-BASED COMPOSITE SANITARY WARE AND PREPARATION METHOD - The invention discloses a resin-based composite sanitary ware, which is characterized in that: the sanitary ware is made by mixing up and injecting the raw materials and then solidifying the mold; and the ingredients of the raw materials and their weight ratios are as follows: unsaturated polyester resin 14%-30%; polyester anti-shrinking medium 6%-14%; reinforcing fiber 11%-37%; scale stone 10%-20%; calcium carbonate 25%-40%; initiator 0.8%-2.4%. And this invention also discloses the preparation method of the sanitary ware. Compared with the current technology, the invention has the advantages of strong strength, high tenacity, perfect self-cleaning capacity and low energy consumption. | 2011-04-28 |
20110098397 | Binder Composition - An aqueous binder composition for a paint comprising an oligomeric or polymeric substance formed from at least one monomer of the general formula I: (R | 2011-04-28 |
20110098398 | Varnish, prepreg, and substrate thereof - A varnish includes an epoxy resin, a curing agent, an accelerator agent and fillers. The fillers include sericite powders. The sericite powders have composition of SiO2 in weight ratio of 55±3%. Furthermore, the Mohs' scale of hardness of the sericite powder is between 2 to 3. Glass fabric cloth is dipped into the varnish so as to form a prepreg with better machined-work capability. | 2011-04-28 |
20110098399 | Cutting Filament for a Trimmer and Method of Producing Such a Cutting Filament - A cutting filament for a manually-guided trimmer, and a method of producing such a filament. A polymeric material is filled with platelet-shaped particles. The filled polymeric material is extruded in the form of a filament blank. In the solidified state, the filament blank is spun in the direction of its longitudinal axis, accompanied by plastic deformation, in such a way that the embedded particles are oriented at least predominantly in the direction of the longitudinal axis. | 2011-04-28 |
20110098400 | Non-yellowing silicone composition - Polyorganosiloxane compositions crosslinkable by polyaddition reactions are provided. Methods for reducing yellowing of a silicone elastomer composition crosslinked by hydrosilylation including adding a polyorganosiloxane resin (D), comprising at least one Si-alkenyl unit, preferably Si-vinyl, to the silicone elastomer composition prior to crosslinking are also provided. | 2011-04-28 |
20110098401 | STYRENE BUTADIENE BLOCK COPOLYMER MIXTURES FOR SHRINK-WRAP FILMS - A mixture which comprises | 2011-04-28 |
20110098402 | FLUOROOXYALKYLENE GROUP-CONTAINING POLYMER COMPOSITION, A SURFACE TREATMENT AGENT COMPRISING THE SAME AND AN ARTICLE TREATED WITH THE AGENT - An object of the present invention is to provide a fluorooxyalkylene group-containing polymer composition, which yields a coating having excellent adhesior to a substrate, good water- and oil-repellency, a low dynamic friction coefficient, good releasing property, good abrasion resistance and good stain resistance, and to provide a surface treatment agent comprising the same. The present inventors have found that a composition comprising a fluorooxyalkylene group-containing polymer having a fluorinated group and a hydrolyzable group at each terminal and a fluorooxyalkylene group-containing polymer having hydrolyzable groups at both terminals can form a coating which has excellent water- and oil-repellency, a low dynamic friction coefficient, good releasing property, good abrasion resistance, and good stain resistance. | 2011-04-28 |
20110098403 | Acrylic Rubber Composition - [Object] To provide: an acrylic rubber composition, which is improved in roll tackiness upon processing and in dough-like-material tackiness between dough-like materials themselves, and which is remarkably improved in processing characteristic, without deteriorating resultant normal physical properties; and an acrylic rubber composition molded and used for a sealing part such as an O-ring, gasket, and packing. | 2011-04-28 |
20110098404 | FUNCTIONAL STYRENE-BUTADIENE COPOLYMER - A functional styrene-butadiene copolymer is disclosed. More specifically, the copolymer is prepared by radical polymerization of a styrene monomer, a butadiene monomer and an epoxy acrylate monomer in an emulsion state and ring-opening of the resultant styrene-butadiene-epoxy acrylate copolymer. When blended with silica, the disclosed copolymer provides excellent wet stopping performance and superior wear resistance. Therefore, it can be usefully applied for industrial materials including fuel-efficient tires, snow tires, belts, hoses, etc. | 2011-04-28 |
20110098405 | Elastomer Nanocomposites With Incorporated Process Oils - This disclosure is directed to nanocomposite compositions that are suitable for air bladders, innertubes, innerliners and other desirable air-retention articles. In particular, this disclosure is directed to compositions that include the nanocomposite, the nanocomposite made in such that its air-retention properties are much improved over what is known, while maintaining desirable elasticity and processability. In a particular aspect, an air-retention article such as an innerliner if formed by first contacting a desirable elastomer, especially a functionalized poly(isobutylene-co-p-methylstyrene) elastomer, with one or more layered fillers such as a clay described further below, and also contacting one or more processing aids, and one or more solvents to form an nanocomposite composition. The nanocomposite composition is then precipitated to form the solid nanocomposite composition which can be dried and further blended with other suitable ingredients such as, for example, curative agents, thus forming an innerliner suitable for a tire or other article. | 2011-04-28 |
20110098406 | Method for Producing High Strength Polyethylene Fiber and High Strength Polyethylene Fiber - The present invention provides a method for producing a high strength polyethylene fiber superior in stretchability and having a higher strength, a higher elastic modulus and high productivity, and a high strength polyethylene fiber produced by the method. The method includes (1) dispersing a chemically surface modified carbon nanofiber in a solvent for an ultrahigh molecular weight polyethylene, (2) preparing a mixed dope comprising the polyethylene, the modified carbon nanofiber and the solvent by mixing the polyethylene with the suspension obtained in (1), wherein the concentration of the polyethylene is not less than 0.5 wt % and less than 50 wt %, and (3) extruding the dope obtained in step (2) through a spinneret, cooling the dope, and then stretching the dope into a filament yarn at a deformation rate of not less than 0.005 s | 2011-04-28 |